



Determination of Interobserver Correlation in the Evaluation of Liver Histopathology of Chronic Hepatitis B Patients and the Reflections on Treatment

Kronik Hepatit B Hastalarının Karaciğer Histopatolojisinin Değerlendirilmesinde Gözlemciler Arası Uyumun Saptanması ve Tedaviye Yansımaları

Yasemin DURDU¹, Zehra Sibel KAHRAMAN², Ayşe Nur TOKSÖZ YILDIRIM³, Ayşe GÖKÇEN SADE⁴,
Ganime ÇOBAN⁵, Merve CİN⁶

¹University of Health Sciences Turkey, Hamidiye Vocational School of Health Services, İstanbul, Turkey

²University of Health Sciences Turkey, Bakırköy Dr. Sadi Konuk Training and Research Hospital, İstanbul, Turkey

³İstanbul Medeniyet University Prof. Dr. Süleyman Yalçın City Hospital, Clinic of Medical Patology, İstanbul, Turkey

⁴University of Health Sciences Turkey, İstanbul Sultan Abdülhamid Han Training and Research Hospital, Clinic of Medical Patology, İstanbul, Turkey

⁵Bezmialem Vakıf University Faculty of Medicine, Department of Medical Patology, İstanbul, Turkey

⁶University of Health Sciences Turkey, Training and Research Hospital, Clinic of Medical Patology, İstanbul, Turkey

ABSTRACT

Objective: Histopathological examination of the liver is the gold standard in the follow-up and treatment of chronic hepatitis B virus (HBV) disease. Ishak's Modified histological activity index (HAI) and fibrosis staging system are usually used in Turkey. Although a common scoring system is used, the same sample can be interpreted differently between different pathologists due to various variables. In this study, the evaluation of liver histopathologies of chronic HBV patients by pathologists in different hospitals and the correlation of the results with each other and the effect on the treatment decision were investigated.

Methods: Pathology slides of liver biopsy materials of 10 patients were evaluated by pathologists in 5 different tertiary care hospitals. Using non-parametric statistical methods, the coefficient of agreement between pathologists was determined. Also, descriptive statistics were used to determine the percentage of receiving treatment.

Results: Agreement between pathologists was calculated the most in total HAI and Fibrosis score ($k=0.8186$, $k=0.8217$). The Kuder-

ÖZ

Amaç: Kronik hepatit B virüsü (HBV) hastalığında takip ve tedavide karaciğerin histopatolojik incelemesi altın standarttır. Türkiye'de histopatolojik değerlendirmede genellikle İshak'ın Modifiye histolojik aktivite indeksi (HAI) ve fibroz evreleme sistemi kullanılmaktadır. Ortak bir skorlama sistemi kullanılmasına rağmen çeşitli değişkenlerden dolayı aynı örnek farklı patoloğlar arasında farklı yorumlanabilmektedir. Bu çalışmada kronik HBV hastalarının karaciğer histopatolojilerinin farklı hastanelerdeki patoloğlarca değerlendirilmesi ve çıkan sonuçların birbirleri ile uyumu ve tedavi kararı üzerindeki etkisi araştırılmıştır.

Yöntemler: Tedavi endikasyonu olup karaciğer biyopsisi yapılan 10 hastaya ait preparatlar 5 farklı 3. basamak hastanesindeki patoloğlar tarafından değerlendirilmiştir. Non-parametrik istatistiksel yöntemler kullanılarak patoloğlar arası uyum katsayısı belirlenmiştir. Ayrıca tedavi alabilme yüzdelерinin belirlenmesi için tanımlayıcı istatistiklere de başvurulmuştur.

Bulgular: Patoloğlar arası uyum en fazla toplam HAI ve Fibroz skorunda hesaplandı ($k=0,8186$, $k=0,8217$). Tedavi kararında

Address for Correspondence: Yasemin DURDU, University of Health Sciences Turkey, Hamidiye Vocational School of Health Services, İstanbul, Turkey

E-mail: yasemin.durdu@sbu.edu.tr **ORCID ID:** orcid.org/0000-0003-3765-8108

Cite this article as: Durdu Y, Kahraman ZS, Toksöz Yıldırım AN, Gökçen Sade A, Çoban G, Cin M. Determination of Interobserver Correlation in the Evaluation of Liver Histopathology of Chronic Hepatitis B Patients and the Reflections on Treatment. Bezmialem Science 2022;10(3):299-304

©Copyright 2022 by the Bezmialem Vakıf University
Bezmialem Science published by Galenos Publishing House.

Received: 29.03.2021

Accepted: 10.05.2021

Richardson reliability coefficient among centres was found to be high in the treatment decision ($k=0.8207$). Although all patients were indicated for treatment according to The European Association for the Study of the Liver 2017 guideline, it was calculated that an average of 58% of the patients could receive treatment according to liver histopathology.

Conclusion: Differences in the pathological diagnosis between pathologists in centres may cause delays in chronic hepatitis B patients' access to treatment.

Keywords: Liver biopsy, liver histopathology, interobserver agreement, Modified Ishak scoring system

merkezler arasındaki Kuder-Richardson Güvenirlik katsayısı yüksek bulundu ($k=0.8207$). Hastaların hepsinin The European Association for the Study of the Liver 2017 kılavuzuna göre tedavi endikasyonu olmasına rağmen, karaciğer histopatolojisine göre ortalama %58 tedavi alabileceği hesaplandı.

Sonuç: Merkezlerdeki patoloğlar arasındaki uyum farklılıkları, kronik HBV hastaların tedaviye ulaşabilmesinde gecikmelere sebep olabilmektedir.

Anahtar Sözcükler: Karaciğer biyopsisi, karaciğer histopatolojisi, gözlemciler arası uyum, Modifiye İshak skorlama sistemi

Introduction

Hepatitis B virus (HBV) is a hepatotropic DNA virus that can cause acute and chronic hepatitis. As a result of chronic diseases caused by HBV, fatal complications such as liver failure, hepatocellular cancer and liver cirrhosis may develop (1). Liver biopsy has an important place in the diagnosis of these complications due to HBV and in deciding the treatment. Many scoring and staging systems have been established in order to increase agreement among pathologists and to establish a standard in the histopathological examination of the liver. While deciding to start treatment in patients with chronic hepatitis B in Turkey, İshak's Modified Histological Activity index (HAI) and İshak's fibrosis staging system (FSS) are generally used (2).

Histopathological examination of the liver is affected by many variables. At the beginning of these variables, there are features related to the biopsy application such as the size of the tissue examined, whether it is fragmented or not, and whether it is taken under the capsule. In addition, errors in the preparation stages, the experience of the pathologist and the scoring systems used can also affect the histopathological examination (3-8).

Modified Ishak scoring examines in detail the main lesions such as interphase hepatitis, confluent necrosis, apoptosis and inflammation. It also makes a detailed evaluation by using 7 different scores in fibrosis staging (Table 1). The fact that Ishak's Modified HAI and fibrosis staging are so detailed increases its distinguishing and descriptive feature, while decreasing its reproducibility (6).

The conditions and rules for providing health services by the state in Turkey are specified in the Health Implementation Communiqué (SUT). According to this communiqué, liver biopsy is mandatory in order to start antiviral therapy in patients with chronic HBV, unless there are contraindications, except for a few exceptional cases (9). In patients with HBV DNA level above 2,000 IU/mL according to SUT, treatment can be started in patients with liver biopsy score of HAI ≥ 6 or FSS ≥ 2 according to Ishak. Scoring systems are important for the standardization of the evaluation of patients, but we can still witness different results reported in the same sample among pathologists in daily practice. One-point differences in the interpretation of scoring

among pathologists can be critical in whether patients receive treatment or not.

Our aim in this study is to determine the consistency of the histopathological examinations of liver biopsy samples obtained from patients with HBV according to the Modified Ishak scoring system among different pathologists in different hospitals and to examine the reflections of the differences in treatment.

Method

Ethics Committee

The ethics committee approval of our study was obtained from the Clinical Research Ethics Committee of Bakırköy Dr Sadi Konuk Training and Research Hospital with the decision number 2019/94.

Material

In our study, 10 patients who were admitted to the infectious diseases outpatient clinics in March 2019 and underwent liver biopsy were included in the study. The histopathological preparations of 10 patients who were planned to be treated for chronic HBV disease and underwent liver biopsy were evaluated by pathologists in five different tertiary care hospitals. A total of 20 preparations stained with Hematoxylin & Eosin and Mason Trichrome stains were evaluated by five different pathologists according to Ishak's Modified HAI and FSS. The results were processed into Excel spreadsheets.

Inclusion/Exclusion Criteria

Patients older than 18 years of age who were followed up for chronic HBV and had phase 2 and phase 4 characteristics according to the EASL (The European Association for the Study of the Liver) 2017 guideline and had liver biopsy indication were included in the study (10). Patients with non-HBV liver disease were excluded from the study. Likewise, patients with contraindications for liver biopsy, pregnant women, and patients whose biopsy material contained less than 5 portal areas were excluded from the study.

Statistical Analysis

Goodness of agreement between pathologists (inter-observer) was evaluated with Kendall's W Coefficient of Agreement,

Table 1. Ishak scoring system

Ishak's Modified histological activity index (grading)	Score
A. Periportal or periseptal interphase hepatitis (piecemeal necrosis)	
None	0
Mild (focal, in the area of several portals)	1
Mild/Moderate (focal, in most of the portal areas)	2
Moderate (in less than 50% of the tracts or septa, with continuity around them)	3
Severe (in more than 50% of tracts or septa, with continuity around them)	4
B. Confluent necrosis	
None	0
Focal confluent necrosis	1
Zone 3 necrosis (in some areas)	2
Zone 3 necrosis (in most areas)	3
Zone 3 necrosis and infrequent portal-central bridging	4
Zone 3 necrosis and numerous portal-central bridging	5
Panacinar or multiacinar necrosis	6
C. Focal (spotty) lytic necrosis, apoptosis and focal inflammation (per 100 magnification)	
None	0
1 or less focus	1
2-4 foci	2
5-10 foci	3
More than 10 foci	4
D. Portal inflammation	
None	0
Mild (in some or all portal areas)	1
Moderate (in some or all portal areas)	2
Moderate/prominent (in all portal areas)	3
Distinct (in all portal areas)	4
Ishak's Fibrosis staging system	Stage
No fibrosis	0
Fibrous enlargement in some portal areas and +/- short fibrous septa	1
Fibrous enlargement of most of the portal areas and +/- short fibrous septa	2
Fibrous expansion and sparse porto-portal bridging (P-P) in most portal areas	3
Fibrous expansion and pronounced bridging of the portal areas [(P-P), as well as Porto-central (P-C) bridging]	4
Rare nodules with pronounced bridging (P-P and/or P-S) (incomplete cirrhosis)	5
Cirrhosis (possible or certain)	6
*Modified from references 2 and 8	

which was one of the non-parametric statistical methods. For this purpose, separate coefficients were calculated for the A, B, C and D categories of the Modified HAI grading system detailed in Table 1. The same was calculated for fibrosis staging and HAI Total score. For treatment, HAI 6 and above and/or fibrosis 2 and above were accepted (according to SUT 2018). However, Kuder-Richardson Confidence coefficient (K-R 20) was calculated because whether or not to receive treatment was yes/no and 0/1 according to binary system. Descriptive statistics were also used when necessary. IBM SPSS 23 package program was used for statistical calculations.

Results

Half of the 10 patients participating in the study were male and half were female, and their ages ranged between 22 and 61. The average age of women was 47 (35-61) and the average age of men was 36.6 (22-57). The data of the patients are given in Table 2.

The histopathological examination results of the centers are summarized in Table 3. HAI results were first given, and then categorical details were given, and FSS was shown in the same table. Inter-observer agreement was high for category A and D scores in HAI grading ($k=0.8186$, $k=0.8217$), but there was no agreement between observers for category B scores in HAI grading (Kendall's W $k<0.5$), and observer-observer agreement for category C scores. Although there was agreement between them, it was not high. The agreement between observers was high in the total score of HAI grading and FSS. In the treatment decision, K-R 20 coefficient was considered reliable because it was above 0.8.

The closer Kendall's coefficient of agreement is to one, the more consistent the scores given by the pathologists are, the closer it is to zero, the more inconsistent the scores are, and it means there is no similarity. The Kuder-Richardson Reliability coefficient (K-R 20) is a value between zero and one, but the closer it is to one, the higher the reliability. The calculated coefficients are given in Table 4.

While all of the current patients (100%) had a treatment indication according to the 2017 EASL guidelines, an average of $58\pm38\%$ had treatment indications considering the histopathology criteria determined by the SUT. Although patients vary according to the centers they go to, the percentage of treatment also varies, and the percentage of receiving treatment according to the centers is $58\pm15\%$ on average. The percentages of receiving treatment are shown in Table 5.

Discussion

Liver histopathology in patients with chronic HBV is still the gold standard for demonstrating liver status. There are several scoring systems developed to create a standard approach in this regard (2). Although these scoring systems were created to ensure harmony between observers, various differences may occur due to the subjective perspective of the observers in the evaluation. While these differences decrease among intracentral

Table 2. Demographic and biochemical characteristics of the patients

	Patient 1	Patient 2	Patient 3	Patient 4	Patient 5	Patient 6	Patient 7	Patient 8	Patient 9	Patient 10
Gender	Male	Female	Male	Female	Female	Male	Male	Female	Male	Female
Age (year)	44	35	57	40	61	28	22	41	32	58
HBeAg	Positive	Positive	Negative	Positive	Negative	Negative	Positive	Negative	Negative	Positive
HBV DNA IU/mL	32,857,266	204,764	14,516	263,113729	64,8241	28,515	180,685,412	25,279	6,664,000	23,764,512
ALT IU/mL	311	215	94	26	44	45	64	28	67	118
AST IU/mL	652	162	59	22	51	33	34	28	41	83
WBC mL	5,420	4,700	7,570	6,500	5,320	8,300	7,700	6,700	10,420	6,270
Hgb g/dL	15.1	9.9	14.6	11.7	13.4	12.3	13.4	12.8	14.4	12.1
PLT 10³/mL	158	323	179	242	149	302	208	201	353	145
MPV fL	11.3	8.8	9.7	10.6	9.3	9.3	10	9.2	11.2	9.8
INR	1.2	0.9	1.04	1.09	1.04	0.9	1.2	0.96	1.1	1.1
GGT IU/L	107	95	15	16	20	25	15	12	22	127
ALP IU/L	92	127	76	29	127	75	68	91	81	157
Alb g/dL	4.3	4.4	3.7	4.5	3.7	3.8	5.1	3.6	3.8	3.8
Glob g/dL	3.5	2.8	4	3	4	2.9	2.4	3.2	3.7	3.9

**Table 3. Scores of the patients according to the centers
HAI total [categories (A+B+C+D)]/fibrosis**

	Center 1	Center 2	Center 3	Center 4	Center 5
Patient 1	3 (1+0+1+1)/1	4 (2+0+1+1)/1	6 (1+1+2+2)/1	4 (1+0+1+2)/1	7 (2+0+2+3)/3
Patient 2	6 (1+0+2+3)/1	6 (2+0+2+2)/2	7 (2+1+1+3)/2	7 (2+1+1+3)/2	7 (2+0+2+3)/4
Patient 3	5 (1+2+1+1)/2	3 (1+0+1+1)/1	4 (1+1+1+1)/1	1 (0+0+1+0)/1	3 (1+0+1+1)/1
Patient 4	6 (1+0+3+2)/0	5 (1+0+2+2)/0	5 (1+0+2+2)/0	3 (1+0+1+1)/1	7 (2+0+2+3)/2
Patient 5	6 (2+0+3+1)/3	6 (1+1+2+2)/3	8 (2+1+3+2)/3	4 (1+0+2+1)/3	10 (3+2+2+3)/5
Patient 6	3 (0+0+2+1)/1	4 (1+0+2+1)/1	4 (1+0+2+1)/1	3 (1+0+1+1)/1	3 (1+0+1+1)/2
Patient 7	2 (0+0+1+1)/2	3 (1+0+1+1)/1	2 (0+0+1+1)/1	3 (1+0+1+1)/2	5 (1+0+2+2)/2
Patient 8	3 (0+0+2+1)/1	4 (0+1+2+1)/0	2 (0+0+1+1)/0	1 (0+0+1+0)/1	3 (1+0+1+1)/1
Patient 9	12 (2+4+3+3)/3	7 (2+1+2+2)/3	10 (3+1+3+3)/3	9 (3+0+3+3)/2	9 (3+0+3+3)/5
Patient 10	10 (4+0+3+3)/6	7 (3+0+2+2)/5	15 (4+4+3+4)/5	6 (3+0+1+2)/4	13 (3+2+4+4)/5

observers, they increase among intercentral observers (4). This situation was also stated in a study published in the Journal of Hepatology, the publication organ of EASL, in 2020 (11).

Today, the most commonly used liver histopathological examination score in patients with chronic HBV is the Modified Isaac scoring system (8). In our study, fibrosis, HAI category A (Interphase hepatitis) and D (portal inflammation) results were found to be highly compatible in the interobserver evaluations in different centers. However, HAI category C (focal necrosis) was found to be acceptable at an acceptable level among observers, while HAI category B (confluent necrosis) was found to be inconsistent. In a study conducted in our country, fibrosis was

Table 4. Calculated coefficients

	Coefficient (*, **)
Category A	0.8186*
Category B	0.3147*
Category C	0.6309*
Category D	0.8217*
HAI total	0.8753*
Fibrosis staging	0.8635*
Treatment decision	0.8207**

*Kendall's coefficient of agreement W, **Kuder-Richardson Confidence coefficient (K-R 20), HAI: Histological activity index

Table 5. Percentages and details of receiving treatment by patients and centers

Can the patient get treatment? (Yes/no)

	Center 1	Center 2	Center 3	Center 4	Center 5	Percentage of receiving treatment
Patient 1	No	No	Yes	No	Yes	40%
Patient 2	Yes	Yes	Yes	Yes	Yes	100%
Patient 3	Yes	No	No	No	No	20%
Patient 4	Yes	No	No	No	Yes	40%
Patient 5	Yes	Yes	Yes	Yes	Yes	100%
Patient 6	No	No	Yes	No	Yes	40%
Patient 7	No	No	No	Yes	Yes	40%
Patient 8	No	No	No	No	No	0%
Patient 9	Yes	Yes	Yes	Yes	Yes	100%
Patient 10	Yes	Yes	Yes	Yes	Yes	100%
Percentage of receiving treatment	60%	40%	60%	50%	80%	

found to be compatible between observers, category D was moderate, and category A and C were weakly compatible. In their study, Westin et al. (4) found the interobserver category C assessment to be of low agreement.

In the presence of cirrhosis, it is common to obtain fragmented tissue during liver biopsy. The presence of fragmentation in the tissue may also cause the fibrosis value to be scored lower (12). The liver lobe where the biopsy is performed may also cause differences in fibrosis scoring. However, even if the lobes from which the biopsy is taken are different, the fibrosis scoring may be consistent between the observers, while the HAI evaluation may be inconsistent between the observers (13).

The ultimate goal in many liver diseases is to prevent liver fibrosis, failure, cirrhosis and hepatocellular carcinoma (14). In studies, it is emphasized that the samples taken by biopsy may not show the pathology in the liver completely due to the fact that liver biopsy samples only 50 thousandths of the liver and that the heterogeneous distribution of chronic viral hepatitis in the liver (14). Nowadays, various serum biomarkers or radiological evaluation methods, in which the elasticity of the liver is measured, are more preferred instead of an invasive method such as biopsy in evaluating the status of the liver in chronic viral HBV infections (1,14).

As far as we can research, there is no study in the literature on how the interobserver agreement, which is another aim of our study, is reflected in the treatment. While all of the patients included in the study had an indication for initiation of treatment according to the 2017 EASL guideline (10), it was found that only 58% of the patients met the indication for initiation of treatment according to the histopathological criteria determined by the SUT. These indication rates vary considerably between centers. This situation may cause delay in initiation of treatment in patients and may cause progression of liver damage.

Study Limitations

The fact that the length of the biopsy specimens and whether they were fragmented were not taken into account was a

limitation of the study. The small number of samples was another limiting factor.

Conclusion

In our country, where histopathological evaluations are accepted as criteria for starting treatment in patients with chronic HBV, incompatibility between observers in different centers may cause differences in treatment initiation rates. This situation needs to be investigated in larger studies.

Ethics

Ethics Committee Approval: The ethics committee approval of our study was obtained from the Clinical Research Ethics Committee of Bakırköy Dr Sadi Konuk Training and Research Hospital with the decision number 2019/94.

Peer-review: Externally peer reviewed.

Authorship Contributions

Surgical and Medical Practices: Z.S.K., A.N.T.Y., A.G.S., G.Ç., M.C., Concept: Y.D., Z.S.K., M.C., Design: Y.D., Z.S.K., A.N.T.Y., A.G.S., G.Ç., M.C., Data Collection or Processing: Y.D., Z.S.K., A.N.T.Y., A.G.S., G.Ç., M.C., Analysis or Interpretation: Y.D., Literature Search: Y.D., Z.S.K., M.C., Writing: Z.S.K.

Conflict of Interest: No conflict of interest was declared by the authors.

Financial Disclosure: Support was received from the University of Health Sciences with the project number 2019/043 from the Scientific Research Coordinator.

References

1. Thio CL, Hawkins C. Hepatitis B Virus. Mandell, Douglas and Bennett's Principles and Practice of Infectious Diseases. Seventh edition 2020. p 1940-63.
2. Ishak K, Baptista A, Bianchi L, Callea F, De Groote J, Gudat F, et al. Histological grading and staging of chronic hepatitis. *J Hepatol* 1995;22:696-9.
3. Mannan R, Misra V, Misra SP, Singh PA, Dwivedi M. A comparative evaluation of scoring systems for assessing Necro-Inflammatory Activity and Fibrosis in liver biopsies of patients with chronic hepatitis. *J Clin Diagn Res* 2014;8:FC08-12.
4. Westin J, Lagging LM, Wejstål R, Norkrans G, Dhillon AP. Interobserver study of liver histopathology using the Ishak score in patients with chronic hepatitis C virus infection. *Liver* 1999;19:183-7.
5. Woynarowski M, Cielecka-Kuszyk J, Kałużyński A, Omulecka A, Sobaniec-Łotowska M, Stolarczyk J, et al. Inter-observer variability in histopathological assessment of liver biopsies taken in a pediatric open label therapeutic program for chronic HBV infection treatment. *World J Gastroenterol* 2006;12:1713-7.
6. Almpanis Z, Demonakou M, Tiniakos D. Evaluation of Liver fibrosis: "Something old, something new..." *Ann Gastroenterol* 2016;29:445-53.
7. Deen-Draisey A, Rao S, Yang G. Pathology in Patients with Chronic Liver Disease. *Clin Liver Dis* 2020;20:361-72.
8. Aydın O, Yıldız L, Kefeli M, Barış S, Kandemir B. Reproducibility of the Ishak Modified Histologic Activity Index in the evaluation of chronic viral hepatitis. *Turk j path* 2005;21:58-61.
9. S U T . <https://www.resmigazete.gov.tr/eskiler/2018/12/20181228M1-1.pdf> 28.12.2018
10. Association for the Study of the Liver. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. European Association for the Study of the Liver. *European J Hepatol* 2017;67:370-98.
11. Davison BA, Harrison SA, Cotter G, Alkhouri N, Sanyal A, Edwards C, et al. Suboptimal reliability of liver biopsy evaluation has implications for randomized Clinical trials. *European J Hepatol* 2020;73:1322-32.
12. Everhart JE, Wright EC, Goodman ZD, Dienstag JL, Hoefs JC, Kleiner DE, et al. Prognostic value of Ishak Fibrosis Stage. Findings from HALT-C trial. *Hepatology* 2010;51:585-94.
13. Regev A, Berho M, Jeffers LJ, Milikowski C, Molina EG, Pyrsopoulos NT, et al. Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection. *The American Journal of Gastroenterology* 2002;97:2614-8.
14. Virarkar M, Morani AC, Taggart MW, Bhosale P. Liver Fibrosis assesment. *Semin Ultrasound CT MR* 2021;42:381-9.
15. Afdhal NH, Nunes D. Evaluation of Liver biopsy: a concise review. *Am J Gastroenterol* 2004;99:1160-74.